Articles related to ‘Rheumatology’
-
Golimumab (Simponi) side effects: risk of serious fungal infections
-
TNF blockers and lymphoma: FDA adds boxed warning
-
Video lecture: Biologic therapies for inflammatory and autoimmune diseases
-
Pregabalin (Lyrica) not approved for fibromyalgia by the EMEA
-
Rubefacients for acute and chronic pain. Podcast review by The Cochrane Collaboration
-
Mechanism of action, indications and adverse effects of: etanercept, infliximab and adalimumab
-
Overview on monoclonal antibody therapy: PPT, images and videos
-
More evidence that bisphosphonates do not increase the risk of atrial fibrillation (AF) or flutter
-
New 2009 NICE clinical guideline for the treatment of rheumatoid arthritis
-
Scottish Medicines Consortium accepted Adalimumab (Humira) for adolescents that do not respond to other DMARDs
-
Flash cards on musculoskeletal system drugs: NSAIDS, DMARDS, and anti-gout agents
-
Cochrane review: Anakinra (Kineret) for reumathoid arthritis has modest efficacy
-
Febuxostat (Adenuric, Ipsen) for the management of hyperuricemia in gout patients. NICE guidance
-
Efalizumab (Raptiva) and progressive multifocal leukoencephalopathy (PML). New safety information
